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Brief Report
Introduction
The identification of the von Willebrand factor-cleaving pro-
tease ADAMTS131 provided new insights into the pathophysiol-
ogy of thrombotic thrombocytopenic purpura (TTP), a life
threatening disorder characterized by thrombocytopenia,
Coombs negative hemolytic anemia and ischemia in various
organs resulting from diffuse platelet thrombi in the microcircu-
lation. The acquired form of the disease is caused by anti-
ADAMTS13 autoantibodies, whereas mutations on
ADAMTS13 gene are responsible for recessively inherited TTP.
Inherited TTP usually develops during childhood, but cases with
adult onset are also being reported, often triggered by events
that induce release from vascular endothelial cells of ultralarge
von Willebrand factor (ULVWF) multimers that are highly reac-
tive with platelets. More than 70 ADAMTS13 gene mutations
have so far been identified in inherited TTP.2-12 Most patients are
compound heterozygotes, but a few homozygotes have also
been reported, particularly in consanguineous families. The
majority of the reported mutations are missense (>50%), fol-
lowed by splice site, nonsense and frameshift mutations. The
majority of mutations are located at the N-terminal of the pro-
tease, emphasizing the importance of these domains in VWF
cleavage. In vitro expression studies have shown that most of the
analyzed mutations determine the clinical and laboratory phe-
notypes through the impairment of ADAMTS13 synthesis
and/or secretion.5,6,9,11,12 Given this, we carried out a molecular
investigation in a large Iranian family with a history of chronic
recurrent TTP, in which both the clinically affected members
presented their first episode of TTP during adulthood. DNA
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The inherited deficiency of ADAMTS13 is usually associat-
ed with severe forms of thrombotic thrombocytopenic pur-
pura. Among the mutations identified in the ADAMTS13
gene, none have been described on the TSP1-6 repeat
domain. We investigated an Iranian family with a history of
chronic recurrent thrombotic thrombocytopenic purpura,
severe ADAMTS13 deficiency and a heterogeneous pattern
of clinical symptoms among affected members. Genetic
analysis revealed a homozygous deletion of nucleotides
2930-2935 (GTGCCC) in exon 23 of ADAMTS13, leading to
the replacement of Cys977 by a Trp and the deletion of
Ala978 and Arg979 in the TSP1-6 repeat domain. To explore
the mechanism of ADAMTS13 deficiency, in vitro expression
studies were performed. Western blotting, pulse-chase label-
ing and immunofluorescence studies demonstrated a secre-
tion pathway defect of the mutant protein, with no intracel-
lular accumulation. This finding is consistent with the
severe ADAMTS13 deficiency but does not explain the het-
erogeneous clinical picture of the 3 siblings carrying the
same mutation.
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analysis identified a homozygous deletion of nucleotides
2930-2935 (GTGCCC) in exon 23 of ADAMTS13 in the 2
probands, but also in one asymptomatic sibling.13 In order
to explain the patients’ phenotype, we then studied the
mechanistic effect of the deletion by means of expression
studies in mammalian cells.
Design and Methods 
Patients 
Two South Iranian patients (2 brothers), off-spring of
first cousins, were affected by chronic recurrent TTP that
first developed during adulthood (Figure 1). Patient II:2, a
26 year old male, had his first episode of TTP at the age of
23 years and 6 subsequent recurrent episodes with no pre-
cipitating event or triggering agent. Bleeding symptoms
such as purpura and petechiae were present at each
episode, accompanied by fever and vomiting, whereas
mild neurological symptoms (visual disorders and drowsi-
ness) were observed only during the first episode. The
clinical diagnosis was established at the time of the first
episode by the presence of thrombocytopenia (platelet
count no higher tha 20×109/L), Coombs negative hemolyt-
ic anemia (Hb 10.3 g/L), fragmented erythrocytes and high
serum level of lactate dehydrogenase (LDH 1055 UI/L).
The patient was successfully treated during each acute
episode with plasma exchange and high dose of corticos-
teroids, before the molecular diagnosis. After his sixth
episode of TTP, to prevent further relapses, the patient
started a prophylactic treatment with fresh frozen plasma
(FFP) (30 ml/kg) every three weeks. Patient II:3, a 31 year
old male, developed his first episode of TTP at the age of
29 years, in association with an episode of pneumonia. He
had purpura and petechiae on his legs, a platelet count of
29×109/L and Coombs negative hemolytic anemia (Hb 8.5
g/L, LDH 954 UI/L). Daily FFP infusions (30 mL/kg) were
effective as reflected by a progressive increase in the
platelet count. Since the first disease episode, the patient
receives an FFP infusion when his platelet count falls
below 100×109/L. According to the family history, anoth-
er male sibling (II:1) had a TTP episode at the age of 23
years and died because of multiorgan failure. Another 4
brothers and one sister are all healthy and have never had
any signs or symptoms of TTP. This study was carried out
with the approval of the local ethics committee 
Ex-vivo analysis 
ADAMTS13 activity and antigen were measured in
plasma samples and in the conditioned media of cells
transfected by wild type (ADAMTS13WT) and mutant
(ADAMTS13del6bp) expression vectors using respectively a
collagen binding assay (CBA) and an immunoassay, both
modified as previously described.14 The presence of neu-
tralizing (inhibitors) and non-neutralizing anti-
ADAMTS13 autoantibodies in patients’ plasma was also
evaluated.14 The coding region and intron–exon bound-
aries of the ADAMTS13 gene (NT_017539) were ampli-
fied and sequenced as previously reported.5
In vitro expression studies
The complete ADAMTS13 wild-type cDNA was insert-
ed into the mammalian expression vector pcDNATM3.1/V5-
His TOPO®TA (Invitrogen, Carlsbad, CA, USA). The dele-
tion of 6 nucleotides from the position 2930 to 2935 of the
ADAMTS13 cDNA (NM_017587) was obtained by site-
directed mutagenesis of ADAMTS13WT expression vector
using a QuickChangeTMSite Directed Mutagenesis Kit
(Stratagene, LaJolla, CA, USA) using forward (5’-
CGGAGGATCCTGTATTGGGCCCATGGGGAG-
GACG-3’) and reverse primers (5’-CGTCCTCCC-
CATGGGCCCAATACAGGATCCTCCG-3’). The pres-
ence of the 6 nucleotides deletion was confirmed by
sequencing analysis. To explore the functional significance
of the mutations, a transient transfection assay was per-
formed as previously described,5 and conditioned media
and lysates of cells transfected by ADAMTS13WT and
ADAMTS13del6bp expression vectors were harvested.
Western blotting analysis
Samples of cell lysates and conditioned media of tran-
siently transfected cells by ADAMTS13WT and
ADAMTS13del6bp expression vectors, adjusted according to
the transfection efficiency as measured by luciferase assay,5
were analyzed by Western blotting using an anti-V5 mono-
clonal antibody against the C-terminal tag of rADAMTS13
(Invitrogen).5 The amount of intracellular and extracellular
rADAMTS13 proteins was quantified by densitometric
analysis using a specific software program (Image Master;
Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Immunofluorescence studies
Immunofluorescence studies were performed on an
African green monkey kidney, SV40 virus transformed cell
line (COS-7), using an anti-V5 monoclonal antibody
against ADAMTS13 and monoclonal antibodies recogniz-
ing the proteins GM130 (a cis-Golgi marker) and Bip-
GRP78 (a chaperone protein involved in Golgi–endoplas-
mic reticulum [ER] transport) (BD Biosciences, Franklin
Lakes, NJ, USA).5
Metabolic labeling studies
Forty-eight hours after transfection, HEK293 cells were
depleted of methionine for 60 min and labeled for 60 min
with 500 µCi/mL PRO-MIXTM (~73% L–[35S] methionine
and ~22% L–[35S] cysteine; Amersham Biosciences,
Uppsala, Sweden). After a chase of 0, 3, 7 and 24 hours,
performed in 1 mL of Opti-MEM I (Invitrogen), condi-
tioned media and cell lysates were harvested adding PMSF
(1 mmol/L) and precleared overnight at 4°C with 300 µL
Staphylococcus aureus Cowan I (SAC) (Sigma-Aldrich,
St.Louis, MO USA) coupled with a rabbit anti-mouse IgG
(Sigma-Aldrich) in NP-40 lysis buffer. Recombinant pro-
teins were immunoprecipitated adding 5 µg of anti-V5
monoclonal antibody (Invitrogen) for three hours at 4°C,
followed by 100 µL of protein A Sepharose (Sigma-
Aldrich) coupled 1:10 with a rabbit anti-mouse IgG (Sigma-
Aldrich) in NP-40 lysis buffer. Resulting pellets were resus-
pended in 40 µl of PAGE sample buffer and denatured at
95°C for five minutes. The immunoprecipitated proteins
were resolved on 8% SDS-PAGE. After five hours of elec-
trophoresis the incorporated radioactivities were read on
dried gels, using Imaging Analyser Typhoon 8600
(Amersham Pharmacia Biotech, Piscataway, NJ, USA).
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Results and Discussion
Figure 1 shows that patients II:2 and II:3 and their
asymptomatic sister (II:4) had a severe ADAMTS13 defi-
ciency. A moderate deficiency of both activity and anti-
gen was observed in the patients’ father (I:1) whereas the
mother (I:2) and one sibling (II:6) had low borderline lev-
els of ADAMTS13 activity and antigen. The remaining
family members had normal ADAMTS13 activity and
antigen levels. No anti-ADAMTS13 autoantibodies (with
or without neutralizing activity) were found in the
patients’ plasma.
Analysis of ADAMTS13 (NT_035014) identified a dele-
tion of 6 nucleotides GTGCCC at position 2930-2935
(c.2930_2935del GTGCCC) in exon 23, leading to the
replacement of Cys977 residue by a Trp and the deletion
of two aminoacids Ala978 and Arg979
(p.C977W+p.A978_R979del)13 in the TSP1-6 repeat
domain of ADAMTS13 protein. Both patients and their
asymptomatic sister (II:4) were homozygotes for this
mutation, their parents and 2 of their brothers (II:6 and
II:7) were heterozygotes (Figure 1). Three common
ADAMTS13 intragenic SNPs p.R7W, p.Q448E and
p.P618A15 were also identified in heterozygous state in
paternal alleles (I:2) and also in II:5 and II:8.
TSP1 repeats are protein modules initially identified in
TSP-1, a multifunctional protein present in platelet α-
granules and released upon their activation. ADAMTS13
has eight TSP1 repeats: the first is located between the
disintegrin-like and the Cys-rich domains; the remaining
seven are located between the spacer domain and the two
C-terminal CUB domains. A few studies support the
views that the seventh and eighth TSP-1 repeats and the
CUB domains are dispensable for protease activity.16 On
the other hand, Majerus et al.17 showed that binding of
ADAMTS13 to immobilized VWF is positively modulat-
ed by the first six C-terminal TSP-1 and CUB domains.
The p.C977W+p.A978_R979del mutation is located in
the TSP1-6 repeat domain, where no mutations have so
far been described. A Secondary Structure Prediction
analysis of this mutation led us to hypothesize an alter-
ation of the correct folding of ADAMTS13: the substitu-
tion of the residue Cys977 with a Trp probably disrupts a
potential disulphide bond within the TSP1-6 domain and
causes a loss of the antiparallel three-stranded fold of the
TSP-1 like domains.18 We also hypothesized that the
unfolded ADAMTS13 protein might be retained in the
cytoplasm causing an impaired secretion and hence the
undetectable ADAMTS13 antigen and activity measured
in patients’ plasma. 
Given this, we performed transient expression studies in
HEK293 that showed a secretion failure of the mutant pro-
tein with a significantly lower concentration than
rADAMTS13WT detected in the cell conditioned media. On
Western blotting the mutant protein rADAMTS13del6bp
appeared as a very weak band, which was estimated to be
5% of the rADAMTS13WT, and by antigen assay
rADAMTS13del6bp was approximately 1% (10 ηg/mL) of
the rADAMTS13WT (870 ηg/mL). The secreted mutant pro-
tein had a normal specific activity (6% of rADAMTS13WT). 
The impairment of ADAMTS13 secretion pathway
was also verified by metabolic labeling studies, showing
that the mutant recombinant protein did not follow the
same protein secretion pathway of the wild-type protein
(Figure 2). rADAMT13WT in cell lysates was maximal at 0
and 3 hours of chase and started to decrease at 7 hours
when the protein was completely secreted. In condi-
tioned media, rADAMTS13WT was barely detectable at 3
hours and then started to accumulate reaching the maxi-
mal concentration at 24 hours. The lysates of cells
expressing rADAMTS13del6bp showed a reduced protein
amount compared to rADAMTS13WT at starting point and
after 3 hours of chase (60% of rADAMTS13WT), and at 7
hours of chase the rADAMTS13del6bp had completely dis-
appeared. In conditioned media, rADAMTS13del6bp was
detectable at 3 hours of chase, with a significant reduced
concentration compared to rADAMTS13WT similar to the
Figure 1. Pedigree of an Iranian family with congenital TTP carrying the c.2930_2935delGTGCCC mutation. Squares and circles indicate
male and female, respectively, and arrows indicate the 2 siblings with symptomatic TTP. Solid circles and squares indicate the presence
of the c.2930_2935delGTGCCC mutation in the homozygous state. The half-solid circles and squares indicate asymptomatic heterozy-
gotes. Plasma levels of ADAMTS13 activity and antigen (given as percentage of pooled normal plasma), measured in the 2 patients
(II:2, II:3) during the remission phase of the disease distantly from FFP infusion, and in all family members, are also shown. The plas-
ma and DNA samples of patient II:1 were not available for phenotype and genotype analysis since the patient had died because of mul-
tiorgan failure. The plasma samples of subject II:7 were not available for phenotype analysis. ND denotes not determined. *Reference
values: 46-116% **Reference values: 45-150%.
ADAMTS13 activity (%)*
ADAMTS13 activity (%)*
ADAMTS13 antigen (%)**
ADAMTS13 antigen (%)**
I:1 I:2
49 24
55 31
II:1 II:2 II:3 II:4 II:5 II:6 II:7 II:8
ND <6 <6 <6 75 44 ND 80
ND <1 <1 <1 70 41 ND 76
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previous experiment (8% of rADAMTS13WT). At 7 hours
of chase the rADAMTS13del6bp was no longer detectable. 
These results were confirmed by immunofluorescence
studies, which showed that the mutant protein was dif-
fusely present throughout the cytoplasm, with only a min-
imal amount localized at ER and cis-Golgi compartments
(Figure 3A-B).The consequences of the 6 nucleotides dele-
tion mutation highlights the importance of proper forma-
tion of disulphide bridges in ADAMTS13 function, as sug-
gested by the identification of as many as 14 additional
missense mutations involving cysteine residues in patients
with inherited TTP.2,3,6,8,9,19
In vitro experiments were carried out in the attempt to
recapitulate the effect of the 6 nucleotides deletion on the
ADAMTS13 secretion pathway and on its protease activ-
ity. The mutant rADAMTS13del6bp protein, although mini-
mally, was secreted and had functional activity. Hence
these experiments failed to fully recapitulate the patients’
plasma pattern (ADAMTS13 antigen and activity were
undetectable). This discrepancy could be due to the pres-
ence of a strong CMV promoter (human cytomegalovirus
immediate-early promoter) inserted in the expression vec-
tor20,21 that may be responsible for the higher ADAMTS13
expression and activity measured in the in vitro experi-
ments. The moderate reduction of ADAMTS13 activity
and antigen levels observed in the patients’ father (I:2)
could also be explained by the presence of the p.P618A
polymorphism, which was previously shown to be asso-
ciated with a severe reduction of ADAMTS13 activity and
antigen levels.22 The patients’ sister (II:4) remained asymp-
tomatic until now at the age of 24 years and has not yet
been pregnant. She has never developed an acute TTP
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Figure 2. Pulse-chase labeling experiments in HEK293 cells trans-
fected with ADAMTS13WT and ADAMTS13dell6p expression vectors.
After 60 minutes-pulse with [35S] methionine, the cells were
chased for 0, 3, 7 and 24 hours. Equivalent amounts of cell
lysates (top) or conditioned media (bottom) for both WT and
mutant constructs were immunoprecipitated using an anti-V5
monoclonal antibody against the C-terminal tag of rADAMTS13
and analyzed by 8% SDS-PAGE. The molecular weight marker is
localized on the left. 
Figure 3. Dual labeling of the recombi-
nant ADAMTS13 proteins and markers
of ER and cis-Golgi compartments. (A)
COS-7 cells transfected with WT and
mutant expression vectors stained
simultaneously with anti-V5 monoclon-
al antibody against rADAMTS13 (green)
and anti-Bip-GRPp78 monoclonal anti-
body (red) against a chaperon protein
of ER compartment. (B) COS-7 cells
transfected with WT and mutant
expression vectors stained simultane-
ously with anti-V5 monoclonal antibody
against rADAMTS13 (green) and anti-
GM130 monoclonal antibody (red)
against a cis-Golgi matrix protein. The
yellow colour demonstrates the colocal-
ization of rADAMTS13WT in both com-
partments whereas cell expressing
rADAMTS13del6bp showed a very faint
dotted yellow colour in both compart-
ments.
Cell lysate
Conditioned media
rADAMTS13WT
rADAMTS13WT
rADAMTS13del6bp
rADAMTS13del6bp
0 3 7 24 0 3 7 24 hr
0 3 7 24 0 3 7 24 hr
kDa
250
150
100
75
50
kDa
250
150
100
75
50
rADAMTS13del6bp
rADAMTS13del6bp
rADAMTS13WT
rADAMTS13WT
V5-FITC GM130-Cy3 V5-FITC+GM130-Cy3
V5-FITC Bip-Cy3 V5-FITC+Bip-Cy3A
B
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episode, in spite of the same homozygous genetic defect
and severe ADAMTS13 deficiency found in her affected
brothers (II:2, II:3). This observation, together with other
previous reports,19,23 shows once again that, in addition to
severe ADAMTS13 deficiency, other as yet obscure
genetic or environmental factors are required for the
onset of TTP, as also shown in a murine model.24
In conclusion this work helped to clarify the mecha-
nism by which the 6 nucleotides deletion mutation caus-
es ADAMTS13 deficiency in congenital TTP. However, it
corroborates the views that ADAMTS13 deficiency is
necessary but not sufficient for the development of this
disease, emphasizing the need to better ascertain addi-
tional factors responsible for TTP pathogenesis. 
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